Stockscreener 앱 받기
0.46%
전일 마감가:
$25.68
열려 있는:
$25.79
하루 거래량:
20.50M
Relative Volume:
0.53
시가총액:
$147.25B
수익:
$63.32B
순이익/손실:
$7.52B
주가수익비율:
19.80
EPS:
1.3043
순현금흐름:
$9.48B
1주 성능:
-1.90%
1개월 성능:
-4.16%
6개월 성능:
+1.13%
1년 성능:
+15.79%
1일 변동 폭
$25.72
$26.18
1주일 범위
$25.60
$26.75
52주 변동 폭
$21.97
$28.75
화이자 Stock (PFE) Company Profile
명칭
Pfizer Inc
전화
(212) 733-2323
주소
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE vs LLY, JNJ, ABBV, AZN, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
25.84 | 146.36B | 63.32B | 7.52B | 9.48B | 1.3043 |
LLY
Lilly Eli Co
|
973.00 | 845.77B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
221.67 | 532.77B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
203.44 | 356.49B | 62.82B | 3.60B | 19.98B | 2.0274 |
AZN
Astrazeneca Plc
|
183.24 | 283.57B | 60.48B | 10.40B | 8.05B | 3.3297 |
NVS
Novartis Ag Adr
|
145.49 | 278.64B | 54.66B | 13.58B | 16.05B | 7.0171 |
화이자 Stock (PFE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-02 | 업그레이드 | Argus | Hold → Buy |
| 2026-02-25 | 개시 | RBC Capital Mkts | Underperform |
| 2026-02-20 | 개시 | Barclays | Underweight |
| 2026-02-12 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2026-01-07 | 재개 | UBS | Neutral |
| 2025-12-02 | 재개 | Citigroup | Neutral |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Neutral |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-11-15 | 개시 | Wolfe Research | Underperform |
| 2024-10-25 | 재개 | Citigroup | Neutral |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-08-07 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | 다운그레이드 | Argus | Buy → Hold |
| 2024-02-23 | 개시 | Guggenheim | Buy |
| 2024-01-04 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | 재개 | UBS | Neutral |
| 2023-10-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-17 | 재확인 | JP Morgan | Neutral |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-06-29 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | 개시 | Jefferies | Hold |
| 2023-02-07 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-01-17 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-12-13 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-04-06 | 재개 | Morgan Stanley | Equal-Weight |
| 2022-01-05 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-01-03 | 재확인 | Bernstein | Mkt Perform |
| 2021-12-20 | 재확인 | Cowen | Outperform |
| 2021-12-17 | 개시 | Goldman | Neutral |
| 2021-12-13 | 업그레이드 | UBS | Neutral → Buy |
| 2021-12-09 | 개시 | Wells Fargo | Overweight |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-05-06 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | 업그레이드 | DZ Bank | Hold → Buy |
| 2020-12-16 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | 재개 | Goldman | Neutral |
| 2020-11-10 | 재개 | Bernstein | Mkt Perform |
| 2020-10-12 | 다운그레이드 | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-06-16 | 개시 | SVB Leerink | Mkt Perform |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-27 | 업그레이드 | Standpoint Research | Hold → Buy |
| 2020-02-06 | 개시 | Mizuho | Buy |
| 2020-01-07 | 개시 | RBC Capital Mkts | Outperform |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-07-30 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | 재개 | Morgan Stanley | Overweight |
| 2019-02-20 | 재개 | Citigroup | Neutral |
| 2019-01-31 | 업그레이드 | Argus | Hold → Buy |
| 2019-01-31 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | 다운그레이드 | UBS | Buy → Neutral |
| 2018-12-11 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-11-01 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
모두보기
화이자 주식(PFE)의 최신 뉴스
BMO Capital Maintains Pfizer(PFE.US) With Buy Rating, Maintains Target Price $34 - Moomoo
Moderna Stock Is Up 6% Today: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax? - 24/7 Wall St.
Pfizer vs Eli Lilly: Different Bets on Pharma M&A - Yahoo Finance
Is Most-Watched Stock Pfizer Inc. (PFE) Worth Betting on Now? - Yahoo Finance Singapore
Pfizer (PFE) Stock; Edges Lower as Investors Weigh Ongoing COVID Franchise Pressure - CoinCentral
Anaveon Announces Presentation of Positive ANV600 Clinical Data at ASCO 2026 and Actively Seeks Partners for its Legacy Oncology Portfolio - GlobeNewswire Inc.
Pfizer Stock Faces a Fresh COVID Patent Overhang as Investors Wait for Its Next Growth Act - TechStock²
Pfizer Advances Oncology Portfolio While Extending Vyndamax Cash Flow Visibility - Yahoo Finance
Pfizer (PFE) Surpasses Q1 Earnings Expectations, Reaffirms 2026 Sales Guidance - GuruFocus
Pfizer Viagra stock: what investors and health-conscious readers need to know in 2026 - Portal CNJ
What Pfizer (PFE)'s Earnings Beat, Reaffirmed Guidance and Oncology Wins Mean For Shareholders - simplywall.st
Great Hill Capital LLC's Pfizer Inc(PFE) Holding History - GuruFocus
GSA CAPITAL PARTNERS LLP's Pfizer Inc(PFE) Holding History - GuruFocus
Pfizer (PFE) Beats EPS Estimates, Reaffirms Full-Year Outlook - GuruFocus
Pfizer Inc. stock (US7170811035): Q1 2026 results and recent share price move - AD HOC NEWS
Opportunities to Drive Change in Alopecia Areata - Pfizer
Here is Why Pfizer (PFE) One of the Best High Volume Stocks to Invest In - Insider Monkey
Pfizer Inc (PFE) Shares Fall 3.0% -- What GF Score of 76 Tells I - GuruFocus
Pfizer Options Spot-On: On May 8th, 207.87K Contracts Were Traded, With 2.63 Million Open Interest - Moomoo
-3.15% for Pfizer stock as new share registration weighs on outlook - Traders Union
Novavax Inc stock (US66987V1098): Shares jump on Q1 beat and Pfizer deal momentum - AD HOC NEWS
Earnings recap: Airbnb, AMD, Shopify, Pfizer, Uber, Arm, Disney… - Proactive financial news
Novavax (NVAX) Soars After Earnings Beat And Pfizer Deal - StocksToTrade
Novavax Stock Jumps As Pfizer Deal Cash Puts Vaccine Turnaround Back In Focus - TechStock²
Pfizer Terminates Early-Stage Cancer Trial: What It Means for PFE Investors - TipRanks
Duavee by Pfizer, Inc - Pharmacy Times
Novavax Stock Jumps As Pfizer Deal And Q1 Beat Energize Traders - timothysykes.com
Assessing Pfizer’s (PFE) Valuation As Shares Hover Near Recent Levels - simplywall.st
Small Molecule Drug Discovery Market Is Going to Boom Rapidly | Pfizer Inc., Merck & Co., Inc., Novartis AG - openPR.com
PFE.DE Technical Analysis | Trend, Signals & Chart Patterns | PFIZER INC (FRA:PFE) - ChartMill
Is Pfizer’s 6.5% Dividend a Yield Trap? Q1 Results Put Speculation to Rest - NAI500
Judge Knocks Out Pfizer Partner's Vax Case Against GSK - Law360
Pfizer Options Spot-On: On May 7th, 299.38K Contracts Were Traded, With 2.62 Million Open Interest - Moomoo
Pfizer Ends Early-Stage Lymphoma Combo Trial, Trimming a Small Piece of Its Oncology Upside - TipRanks
Pfizer’s Next Lyme Shot: What a Fifth-Dose VLA15 Trial Signals for PFE Investors - TipRanks
Novavax, Inc. Stock Jumps: Why Pfizer’s Matrix-M Deal Drove a Surprise Q1 Revenue Beat - TechStock²
Inside the Pfizer CentreOne OSD Network - Contract Pharma
Analysts Conflicted on These Healthcare Names: Pfizer (PFE), Spyre Therapeutics (SYRE) and Adaptive Biotechnologies (ADPT) - The Globe and Mail
Is Pfizer Stock Worth Buying After a Q1 2026 Beat and Patent Win? - TIKR.com
Pfizer Works to Address Inequities in IBD Care - Pfizer
Pfizer's 6.5% Dividend Yield Looked Too Good to Be True -- but Management Just Silenced the Skeptics - Yahoo Finance
How Pfizer’s Q1 Beat, Oncology Wins and Patent Deals At Pfizer (PFE) Has Changed Its Investment Story - Yahoo Finance
Is It Time To Reconsider Pfizer (PFE) After Recent Share Price Rebound? - simplywall.st
Pfizer and Our CEO Albert Bourla Recognized by TIME, Fortune - Pfizer
CEO Albert Bourla Reflects on Pfizer’s Year of Bold Moves and Relentless Innovation in 2025 Annual Review - Pfizer
Pfizer To Go Ex-Dividend On May 8th, 2026 With 0.43 USD Dividend Per Share - Moomoo
AI in Healthcare? Pfizer, Anthropic, and Longevity Scientists Think It’s Critical - Yahoo Finance
Pfizer Earnings Call Highlights Growth Beyond COVID - The Globe and Mail
Interviews: How To Upskill In A Lockdown - Pfizer
Tunica-Biloxi Tribe receives grant from Pfizer to expand healthcare in Central Louisiana - WGNO
Novavax (NVAX) Finds a New Revenue Engine in Pfizer Licensing - AlphaStreet
화이자 (PFE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.04%
0.43%
자본화:
|
볼륨(24시간):